Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Irritable bowel syndrome (IBS) is the most common gastrointestinal (GI) disorder worldwide, however treatment options for diarrhea-predominant IBS (IBS-D) remain limited. Eluxadoline, a µ- and κ-opioid receptor agonist and δ-opioid receptor antagonist, was recently approved for the treatment of IBS-D. A novel compound first described in 2008, eluxadoline was shown to normalize GI transit, with a subsequent phase I demonstrating its safety and tolerability in healthy adults. In 2016, two randomized, double-blind, placebo-controlled phase III trials studying eluxadoline use at 75 mg and 100 mg twice daily over 26 weeks demonstrated a significant improvement in stool consistency and many global symptoms of IBS. However, the data did not demonstrate a significant advantage over placebo using the United States Food and Drug Administration (US FDA) and European Medicines Agency (EMA) endpoints for abdominal pain. Safety and tolerability data, pooled from both phase II and III studies, suggest that eluxadoline is generally well tolerated with the most common adverse events (AEs) occurring in approximately 3–8% of patients and included nausea, constipation, and abdominal pain. The most common serious adverse event (SAE) is pancreatitis, which had a 0.4% incidence. Recent US FDA reports reporting severe pancreatitis and sphincter of Oddi dysfunction after short-term use of eluxadoline in patients without a gallbladder has added a history of cholecystectomy as an important contraindication. Eluxadoline is also contraindicated in patients with a history of biliary duct obstruction, sphincter of Oddi dysfunction, active alcohol abuse, history of pancreatitis or known pancreatic duct obstruction, severe hepatic impairment, severe or chronic constipation, or known mechanical gastrointestinal obstruction. As a new drug to enter the IBS-D market, the place of eluxadoline in the hierarchy of IBS treatments is still to be determined. In this article, we review the development and clinical trial data behind the approval of eluxadoline with a focus on safety data and its use in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Eluxadoline is a μ-opioid and κ-opioid receptor agonist and δ-opioid receptor antagonist licensed for IBS-D. The drug slows intestinal transit and reduces visceral hypersensitivity. 229”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [229]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Irritable Bowel Syndrome: A Clinical Review
Chey, W. D., Kurlander, J., & Eswaran, S. (2015) · JAMA · doi:10.1001/jama.2015.0954 · Cited by 1,081
Opioid receptors in the gastrointestinal tract
Holzer, P. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.03.012 · Cited by 377
Eluxadoline for Irritable Bowel Syndrome with Diarrhea
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505180 · Cited by 334
Lembo, A., Pimentel, M., Rao, S. S., Schoenfeld, P., Cash, B., Weinstock, L. B., Paterson, C., Bortey, E., & Forbes, W. P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.003 · Cited by 310
Role of loperamide and placebo in management of irritable bowel syndrome (IBS)
Cann, P. A., Read, N. W., Holdsworth, C. D., & Barends, D. (1984) · Digestive Diseases and Sciences · doi:10.1007/bf01296258 · Cited by 257
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., Henry, A., Hall, I., Whorwell, P., & Spiller, R. (2014) · Gut · doi:10.1136/gutjnl-2013-305989 · Cited by 246
Andresen, V., Montori, V. M., Keller, J., West, C. P., Layer, P., & Camilleri, M. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.12.015 · Cited by 208
A Double-Blind Placebo-Controlled Trial with Loperamide in Irritable Bowel Syndrome
Efskind, P. S., Bernklev, T., & Vatn, M. H. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609006766 · Cited by 206
Loperamide in Treatment of Irritable Bowel Syndrome—A Double-Blind Placebo Controlled Study
Lävo, B., Stenstam, M., & Nielsen, A.-L. (1987) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528709091003 · Cited by 175
Research works printed but not linked: 1
- Mullard A., 2015, Nat Rev Drug Discov, 14, 449
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Sex-gender differences in irritable bowel syndrome
Kim, Y. S., & Kim, N. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18082 · Cited by 322
Black, C. J., Burr, N. E., Camilleri, M., Earnest, D. L., Quigley, E. M., Moayyedi, P., Houghton, L. A., & Ford, A. C. (2020) · Gut · doi:10.1136/gutjnl-2018-318160 · Cited by 191
Metadata
- Authors
- Barshop, K., & Staller, K.
- Affiliations
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Staller, Kyle
- Venue
- Therapeutic Advances in Chronic Disease
- Publisher
- SAGE Publications
- Published
- 2017-06-21
- Volume
- 8
- Issue
- 11
- Pages
- 153-160
- ISSN
- 2040-6223 (ISSN-L)
- 2040-6231
- PMC
- PMC5638229
- OpenAlex
- W2642309412
- Cited by
- 25
- References
- 27
- Citations by year
- 2026: 2 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 2
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Chronic Disease (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- eluxadoline, irritable bowel syndrome with diarrhea, opioid agonists, delta-opioid receptor antagonists, pancreatitis, sphincter of Oddi dysfunction, drug safety and tolerability, drug approval, gastrointestinal transit, treatment hierarchy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy. https://app.cochat.ai/papers/10.1177/2040622317714389
- The paper
- Barshop, K., & Staller, K. (2017). Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy. Therapeutic Advances in Chronic Disease. https://doi.org/10.1177/2040622317714389
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.